Toll样受体介导的肠道免疫研究进展

黏膜免疫系统的第一道防线——肠黏膜上皮,不但能区分和识别致病菌和共生菌,而且能启动适当的免疫应答。在机体正常情况下,肠黏膜上皮细胞（IEC）对肠道共生菌持耐受状态,维持肠道内环境的稳定。IEC能识别致病菌的危险信号,激活派伊尔结节,启动免疫应答。有关实验已证实肠黏膜上皮针对肠腔细菌呈“耐受”或“非耐受”状态,主要依赖于Toll样受体（TLRS）介导的信号转导通路。     

Toll样受体与抗结核感染免疫

结核分枝杆菌(MTB)是结核病的致病菌,其发病机制仍未阐明。Toll样受体(TLR)蛋白家族属于动物模式识别受体家族。研究表明,TLR对先天免疫和获得性免疫都有调控作用,与抗结核感染免疫有关的主要是TLR2和TLR4。对TLR的研究为MTB诱导先天免疫反应机制的阐明以及治疗方法的进步提供了新的思路。     

靶向 Toll 样受体的免疫调节剂研究进展

Toll 样受体是一类相对保守的模式识别受体,可以识别损伤相关分子模式和病原相关分子模式,从而启动天然免疫应答,在天然免疫过程中发挥非常重要的作用。其介导的信号通路失调会引发各种炎症反应、癌症和自身免疫病等疾病。综述近年与 Toll 样受体有关的免疫调节剂的研究进展,并概括与之相关的疾病,为靶向 Toll 样受体的免疫调节剂的研发提供一定参考。     

Toll样受体在抗感染免疫中的作用

目前已确认的人类Toll样受体有10个,它们分别识 病原微生物不同的病原体相关分子特式结构,其中TLR9与细菌CpG-DNA关系的发现,受到人们普遍的重视和关注,本文简要地介绍细菌CpG基序与TLR9,鞭毛蛋白与TLR5和病毒与TLR5等的相互关系及其意义。     

Toll样受体的研究进展

Toll样受体是近几年发现的天然免疫受体,它们不仅能特异性地识别病原微生物的结构成分,激活天然免疫,同时也为激活获得性免疫提供共刺激信号。Toll样受体是天然免疫与获得性免疫之间的连接点。     

Toll样受体与抗真菌感染免疫

Toll样受体是一类保守的天然免疫识别受体家族,可识别众多微生物共有的保守模式分子——病原体相关分子模式,通过某些信号转导途径,激发机体先天性及获得性免疫应答,引起炎症介质的释放。数个真菌细胞壁成分可被Toll样受体识别,不同的白细胞介素1受体／Toll样受体超家族成员通过MyD88的相互作用,激活Toll样受体信号转导通路,从而诱导宿主抵抗真菌的攻击。     

Toll 样受体与天然免疫

Toll样受体家族是一类模式识别受体,它介导了一个植物,昆虫,哺乳动物共同拥有的高度保守的信号通路。最近几年相继发现了多种人类Toll样受体以及相关的病原微生物配体,这些配体涵盖了病毒,细菌,真菌等微生物上多种保守的病原相关分子模式。可见Toll样受体在多种病原微生物及其产物的识别和免疫防御反应中有重要的作用。     

天然免疫进化中的无脊椎动物Toll样受体

Toll样受体（Toll-like receptors,TLR）（或Toll）通过与各种病原相关分子模式（pathogen associated molecular patterns,PAMP）的识别和特异结合,广泛参与各种天然免疫应答,目前已在线虫类、软体动物、节肢动物、棘皮动物及低等脊索类的后口动物等多种无脊椎动物中发现大量的TLR及同源蛋白.TLR在进化中高度保守,其功能随着动物进化中免疫机能的复杂化而多样化.这些研究成果将会不断加深对无脊椎动物天然免疫系统的起源、进化路线及其信号转导机制的认识.     

Toll 样受体研究进展

Toll样受体（Toll－like receptors,TLRs）是新近发现的先天性免疫系统中的细胞跨膜受体及病原模式识别受体之一,在急性炎症反应细胞吞噬作用的调节和细胞信号转导及细胞凋亡中起重要作用,简要综述了Toll样受体的发现、分布、基因定位与结构特点、配体特异性及其介导的信号通路,并对其研究意义与前景作了简述。     

病毒感染对宿主TLRs模式识别与免疫应答信号的影响

TLRs是一类古老的天然模式识别分子,通过识别病毒的PAMPs,活化依赖和非依赖于MyD88的信号通路,诱导IFNs、促炎性细胞因子和趋化因子等分子的释放和表达,清除病毒的感染;同时,病毒为了感染宿主,采用多种免疫逃避策略干扰机体TLRs的信号,尤其调节MyD88、NF-κB、TRIF和IRFs等重要信号分子,以逃避机体天然PRRs的监视、识别和清除。因此,本文重点以VACV、HCV和HIV为例,介绍病毒感染对宿主TLRs模式识别与免疫应答信号的调节,以进一步理解病毒与宿主相互作用的复杂性,为病毒病的有效防治提供理论依据。     

Interleukin 18: Friend or foe in cancer

In the last few years, the field of tumor immunology has significantly expanded and its boundaries, never particularly clear, have become less distinct. Although the immune system plays an important role in controlling tumor growth, it has also become clear that tumor growth can be promoted by inflammatory immune responses. A good example that exemplifies the ambiguous role of the immune system in cancer progression is represented by interleukin 18 (IL-18) that was first identified as an interferon-γ-inducing factor (IGIF) involved in T helper type-1 (Th1) immune response. The expression and secretion of IL-18 have been observed in various cell types from immune cells to circulating cancer cells. In this review we highlighted the multiple roles played by IL-18 in immune regulation, cancer progression and angiogenesis and the clinical potential that may result from such understanding.     

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

Numerous phase I and II clinical trials testing the safety and immunogenicity of various peptide vaccine formulations based on CTL-defined tumor antigens in cancer patients have been reported during the last 7 years. While specific T-cell responses can be detected in a variable fraction of immunized patients, an even smaller but significant fraction of these patients have objective tumor responses. Efficient therapeutic vaccination should aim at boosting naturally occurring antitumor T- and B-cell responses and at sustaining a large number of tumor antigen specific and fully functional effector T cells at tumor sites. Recent progress in our ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.This work was presented at the first Cancer Immunology and Immunotherapy Summer School, 8–13 September 2003, Ionian Village, Bartholomeio, Peloponnese, Greece.     

Toll-like receptors expressed in tumor cells: targets for therapy

Toll-like receptors (TLRs), mainly expressing in human immune related cells and epithelial cells, play an essential role in the host defense against microbes by recognizing conserved bacterial molecules. Recently, the expression or up-regulation of TLRs has been detected in many tumor cell lines or tumors, especially epithelial derived cancers. Although the TLR profile varies on different tumor cells, the current evidences indicate that the expression of TLRs is functionally associated with tumor progression. TLR expression may promote malignant transformation of epithelial cells. Engagement of TLRs increases tumor growth and tumor immune escape, and induces apoptosis resistance and chemoresistance in some tumor cells. These findings demonstrate that TLR is a promising target for the development of anticancer drugs and make TLR agonists or antagonists the potential agents for tumor therapy.     

Murine mammary carcinoma cells and CD11c dendritic cells elicit distinct responses to lipopolysaccharide and exhibit differential expression of genes required for TLR4 signaling

Although TLR are often studied on DC because of their ability to bridge innate and adaptive defenses, TLR are also expressed by epithelial cells. Because the majority of cancers are carcinomas, and thus of epithelial origin, we wanted to know whether a carcinoma and DC responded similarly to a TLR agonist. We found the mammary carcinoma 4T1 and CD11c⁺ DC both secreted proinflammatory chemokines in response to the TLR4 agonist lipopolysaccharide (LPS). However a clear dichotomy existed. DC, but not 4T1 secreted IL-1β, TNF-α, and upregulated CD80 and CD86 expression following LPS treatment. A potential reason for differential responsiveness was that DC expressed greater levels of TLR4, CD14, Myd88, and TRAM. Despite the low level of TLR signaling proteins, the carcinoma were able to elicit a range of responses contingent upon the source, dose, length, and frequency of TLR agonist treatment. Thus, carcinoma and DC are distinctly responsive to LPS.     

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. In contrast to B7-1 and B7-2, PD-L1 does not interact with either CD28 or CTLA-4. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-1 gene–deficient mice developed autoimmune diseases, which early led to the hypothesis of PD-L1 regulating peripheral tolerance. In contrast to normal tissues, which show minimal surface expression of PD-L1 protein, PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN- stimulation. Thus, PD-L1 might play an important role in tumor immune evasion. This review discusses the currently available data concerning negative T-cell regulation via PD-1, the blockade of PD-L1/PD-1 interactions, and the implications for adoptive T-cell therapies.